Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.

Rawat V, Wang S, Sima J, Bar R, Liraz O, Gundimeda U, Parekh T, Chan J, Johansson JO, Tang C, Chui HC, Harrington MG, Michaelson DM, Yassine HN.

J Neurosci. 2019 Nov 27;39(48):9611-9622. doi: 10.1523/JNEUROSCI.1400-19.2019. Epub 2019 Oct 22.

PMID:
31641056
2.

Extra-Hippocampal Learning Deficits in Young Apolipoprotein E4 Mice and Their Synaptic Underpinning.

Har-Paz I, Roisman N, Michaelson DM, Moran A.

J Alzheimers Dis. 2019;72(1):71-82. doi: 10.3233/JAD-190564.

PMID:
31561365
3.

ApoE4 Exacerbates Hippocampal Pathology Following Acute Brain Penetration Injury in Female Mice.

Ben-Moshe H, Luz I, Liraz O, Boehm-Cagan A, Salomon-Zimri S, Michaelson D.

J Mol Neurosci. 2020 Jan;70(1):32-44. doi: 10.1007/s12031-019-01397-7. Epub 2019 Sep 5. Review.

PMID:
31489583
4.

The Effects of APOE4 on Mitochondrial Dynamics and Proteins in vivo.

Simonovitch S, Schmukler E, Masliah E, Pinkas-Kramarski R, Michaelson DM.

J Alzheimers Dis. 2019;70(3):861-875. doi: 10.3233/JAD-190074.

PMID:
31306119
5.

ApoE4: an emerging therapeutic target for Alzheimer's disease.

Safieh M, Korczyn AD, Michaelson DM.

BMC Med. 2019 Mar 20;17(1):64. doi: 10.1186/s12916-019-1299-4. Review.

6.

The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo.

Salomon-Zimri S, Koren A, Angel A, Ben-Zur T, Offen D, Michaelson DM.

Curr Alzheimer Res. 2019;16(4):281-292. doi: 10.2174/1567205016666190228120254.

PMID:
30819082
7.

De novo assembly of a transcriptome for the cricket Gryllus bimaculatus prothoracic ganglion: An invertebrate model for investigating adult central nervous system compensatory plasticity.

Fisher HP, Pascual MG, Jimenez SI, Michaelson DA, Joncas CT, Quenzer ED, Christie AE, Horch HW.

PLoS One. 2018 Jul 11;13(7):e0199070. doi: 10.1371/journal.pone.0199070. eCollection 2018.

8.

The Interplay Between Apolipoprotein E4 and the Autophagic-Endocytic-Lysosomal Axis.

Schmukler E, Michaelson DM, Pinkas-Kramarski R.

Mol Neurobiol. 2018 Aug;55(8):6863-6880. doi: 10.1007/s12035-018-0892-4. Epub 2018 Jan 20. Review.

PMID:
29353455
9.

The effects of apolipoprotein E genotype, α-synuclein deficiency, and sex on brain synaptic and Alzheimer's disease-related pathology.

Bar R, Boehm-Cagan A, Luz I, Kleper-Wall Y, Michaelson DM.

Alzheimers Dement (Amst). 2017 Sep 6;10:1-11. doi: 10.1016/j.dadm.2017.08.003. eCollection 2018.

10.

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.

Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, Cella D, Gupta RT, Bhatt R, Van Allen E, Lara P, Choueiri TK, Kapoor A, Heng DYC, Shuch B, Jewett M, George D, Michaelson D, Carducci MA, McDermott D, Allaf M.

Kidney Cancer. 2017 Jul 26;1(1):31-40. doi: 10.3233/KCA-170010. Review.

11.

Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Grimm MOW, Michaelson DM, Hartmann T.

J Lipid Res. 2017 Nov;58(11):2083-2101. doi: 10.1194/jlr.R076331. Epub 2017 May 20. Review.

12.

Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins.

Boehm-Cagan A, Bar R, Harats D, Shaish A, Levkovitz H, Bielicki JK, Johansson JO, Michaelson DM.

PLoS One. 2016 Nov 8;11(11):e0166195. doi: 10.1371/journal.pone.0166195. eCollection 2016.

13.

ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.

Boehm-Cagan A, Bar R, Liraz O, Bielicki JK, Johansson JO, Michaelson DM.

J Alzheimers Dis. 2016 Oct 4;54(3):1219-1233.

PMID:
27567858
14.

Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment.

Salomon-Zimri S, Glat MJ, Barhum Y, Luz I, Boehm-Cagan A, Liraz O, Ben-Zur T, Offen D, Michaelson DM.

J Alzheimers Dis. 2016 Jun 30;53(4):1443-58. doi: 10.3233/JAD-160182.

PMID:
27372644
15.

Behavioral testing affects the phenotypic expression of APOE ε3 and APOE ε4 in targeted replacement mice and reduces the differences between them.

Salomon-Zimri S, Liraz O, Michaelson DM.

Alzheimers Dement (Amst). 2015 Apr 15;1(2):127-35. doi: 10.1016/j.dadm.2014.11.014. eCollection 2015 Jun.

16.

An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo.

Luz I, Liraz O, Michaelson DM.

Curr Alzheimer Res. 2016 Jun 2;13(8):918-29.

PMID:
27040139
17.

Impaired Autophagy in APOE4 Astrocytes.

Simonovitch S, Schmukler E, Bespalko A, Iram T, Frenkel D, Holtzman DM, Masliah E, Michaelson DM, Pinkas-Kramarski R.

J Alzheimers Dis. 2016;51(3):915-27. doi: 10.3233/JAD-151101.

PMID:
26923027
18.

Correction: Targeting Homologous Recombination in Notch-Driven C. elegans Stem Cell and Human Tumors.

Deng X, Michaelson D, Tchieu J, Cheng J, Rothenstein D, Feldman R, Lee SG, Fuller J, Haimovitz-Friedman A, Studer L, Powell S, Fuks Z, Albert Hubbard EJ, Kolesnick R.

PLoS One. 2016 Jan 22;11(1):e0141673. doi: 10.1371/journal.pone.0141673. eCollection 2016. No abstract available.

19.

Cell cycle features of C. elegans germline stem/progenitor cells vary temporally and spatially.

Roy D, Michaelson D, Hochman T, Santella A, Bao Z, Goldberg JD, Hubbard EJA.

Dev Biol. 2016 Jan 1;409(1):261-271. doi: 10.1016/j.ydbio.2015.10.031. Epub 2015 Nov 11.

20.

The effects of the apoE4 genotype on the developing mouse retina.

Maharshak I, Salomon-Zimri S, Antes R, Liraz O, Nisgav Y, Livnat T, Weinberger D, Colton CA, Solomon AS, Michaelson DM.

Exp Eye Res. 2016 Apr;145:17-25. doi: 10.1016/j.exer.2015.11.001. Epub 2015 Nov 7.

PMID:
26554939
21.

Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice.

Dolejší E, Liraz O, Rudajev V, Zimčík P, Doležal V, Michaelson DM.

J Neurochem. 2016 Feb;136(3):503-9. doi: 10.1111/jnc.13417. Epub 2015 Nov 19.

22.

Targeting Homologous Recombination in Notch-Driven C. elegans Stem Cell and Human Tumors.

Deng X, Michaelson D, Tchieu J, Cheng J, Rothenstein D, Feldman R, Lee SG, Fuller J, Haimovitz-Friedman A, Studer L, Powell S, Fuks Z, Hubbard EJ, Kolesnick R.

PLoS One. 2015 Jun 29;10(6):e0127862. doi: 10.1371/journal.pone.0127862. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0141673.

23.

VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina.

Antes R, Salomon-Zimri S, Beck SC, Garcia Garrido M, Livnat T, Maharshak I, Kadar T, Seeliger M, Weinberger D, Michaelson DM.

Curr Alzheimer Res. 2015;12(4):323-34.

PMID:
25817253
24.

Irises: A practical tool for image-based analysis of cellular DNA content.

Vogel JL, Michaelson D, Santella A, Hubbard EJ, Bao Z.

Worm. 2014 May 8;3:e29041. doi: 10.4161/worm.29041. eCollection 2014.

25.

APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.

Michaelson DM.

Alzheimers Dement. 2014 Nov;10(6):861-8. doi: 10.1016/j.jalz.2014.06.015. Epub 2014 Sep 10. Review.

PMID:
25217293
26.

Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.

Boehm-Cagan A, Michaelson DM.

J Neurosci. 2014 May 21;34(21):7293-301. doi: 10.1523/JNEUROSCI.5198-13.2014.

27.

Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo.

Gilat-Frenkel M, Boehm-Cagan A, Liraz O, Xian X, Herz J, Michaelson DM.

Curr Alzheimer Res. 2014;11(6):549-57.

28.

Hippocampus-related cognitive impairments in young apoE4 targeted replacement mice.

Salomon-Zimri S, Boehm-Cagan A, Liraz O, Michaelson DM.

Neurodegener Dis. 2014;13(2-3):86-92. doi: 10.1159/000354777. Epub 2013 Sep 24.

PMID:
24080852
29.

Opposing actions of environmental enrichment and Alzheimer's disease on the expression of hippocampal microRNAs in mouse models.

Barak B, Shvarts-Serebro I, Modai S, Gilam A, Okun E, Michaelson DM, Mattson MP, Shomron N, Ashery U.

Transl Psychiatry. 2013 Sep 10;3:e304. doi: 10.1038/tp.2013.77.

30.

ApoE4 induces synaptic and ERG impairments in the retina of young targeted replacement apoE4 mice.

Antes R, Ezra-Elia R, Weinberger D, Solomon A, Ofri R, Michaelson DM.

PLoS One. 2013 May 31;8(5):e64949. doi: 10.1371/journal.pone.0064949. Print 2013.

31.

ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice.

Liraz O, Boehm-Cagan A, Michaelson DM.

Mol Neurodegener. 2013 May 17;8:16. doi: 10.1186/1750-1326-8-16.

32.

ApoE ε4 is associated with eIF2α phosphorylation and impaired learning in young mice.

Segev Y, Michaelson DM, Rosenblum K.

Neurobiol Aging. 2013 Mar;34(3):863-72. doi: 10.1016/j.neurobiolaging.2012.06.020. Epub 2012 Aug 9.

PMID:
22883908
33.

Sensory regulation of the C. elegans germline through TGF-β-dependent signaling in the niche.

Dalfó D, Michaelson D, Hubbard EJ.

Curr Biol. 2012 Apr 24;22(8):712-9. doi: 10.1016/j.cub.2012.02.064. Epub 2012 Apr 5.

34.

The effects of apolipoproteins E3 and E4 on the transforming growth factor-β system in targeted replacement mice.

Haas A, Liraz O, Michaelson DM.

Neurodegener Dis. 2012;10(1-4):41-5. doi: 10.1159/000334902. Epub 2012 Feb 1.

PMID:
22301441
35.

The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol.

Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, Lütjohann D, Broersen LM, Hartmann T, Michaelson DM.

J Alzheimers Dis. 2012;28(3):667-83. doi: 10.3233/JAD-2011-111265.

PMID:
22057027
36.

Anatomical localization of protease-activated receptor-1 and protease-mediated neuroglial crosstalk on peri-synaptic astrocytic endfeet.

Shavit E, Michaelson DM, Chapman J.

J Neurochem. 2011 Nov;119(3):460-73. doi: 10.1111/j.1471-4159.2011.07436.x. Epub 2011 Sep 23.

37.

ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function.

Zepa L, Frenkel M, Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM.

Int J Alzheimers Dis. 2011 Feb 15;2011:792070. doi: 10.4061/2011/792070.

38.

Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.

Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM.

J Alzheimers Dis. 2010;22(3):959-70. doi: 10.3233/JAD-2010-101008.

39.

Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade.

Inbar D, Belinson H, Rosenman H, Michaelson DM.

Neurodegener Dis. 2010;7(1-3):16-23. doi: 10.1159/000283477. Epub 2010 Feb 13.

PMID:
20160452
40.

Insulin signaling promotes germline proliferation in C. elegans.

Michaelson D, Korta DZ, Capua Y, Hubbard EJ.

Development. 2010 Feb;137(4):671-80. doi: 10.1242/dev.042523. Erratum in: Development. 2014 Jan;141(1):237.

41.

Blood cholinesterases from Washington State orchard workers.

Wilson BW, Henderson JD, Furman JL, Zeller BE, Michaelsen D.

Bull Environ Contam Toxicol. 2009 Jul;83(1):59-61. doi: 10.1007/s00128-009-9724-6. Epub 2009 Apr 23. Erratum in: Bull Environ Contam Toxicol. 2009 Sep;83(3):462. Michaelson, David [corrected to Michaelsen, David].

42.

ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum.

Belinson H, Michaelson DM.

J Neural Transm (Vienna). 2009 Nov;116(11):1427-34. doi: 10.1007/s00702-009-0218-9. Epub 2009 Apr 16.

PMID:
19370389
43.

Pathological synergism between amyloid-beta and apolipoprotein E4--the most prevalent yet understudied genetic risk factor for Alzheimer's disease.

Belinson H, Michaelson DM.

J Alzheimers Dis. 2009;17(3):469-81. doi: 10.3233/JAD-2009-1065. Review.

PMID:
19363257
44.

Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background.

Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, Pick CG, Shoenfeld Y, Korczyn AD, Chapman J.

Neurobiol Aging. 2011 Feb;32(2):272-9. doi: 10.1016/j.neurobiolaging.2009.02.007. Epub 2009 Mar 12.

PMID:
19282067
45.

Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits.

Belinson H, Lev D, Masliah E, Michaelson DM.

J Neurosci. 2008 Apr 30;28(18):4690-701. doi: 10.1523/JNEUROSCI.5633-07.2008.

46.

Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division.

Michaelson D, Abidi W, Guardavaccaro D, Zhou M, Ahearn I, Pagano M, Philips MR.

J Cell Biol. 2008 May 5;181(3):485-96. doi: 10.1083/jcb.200801047. Epub 2008 Apr 28.

47.

Activation of the amyloid cascade by intracerebroventricular injection of the protease inhibitor phosphoramidon.

Nisemblat Y, Belinson H, Dolev I, Michaelson DM.

Neurodegener Dis. 2008;5(3-4):166-9. doi: 10.1159/000113692. Epub 2008 Mar 6.

PMID:
18322380
48.

Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.

Levi O, Dolev I, Belinson H, Michaelson DM.

J Neurochem. 2007 Nov;103(3):1031-40. Epub 2007 Jul 31.

49.

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.

Cancer. 2007 Aug 1;110(3):556-63.

50.

The nucleation growth and reversibility of Amyloid-beta deposition in vivo.

Dolev I, Michaelson DM.

J Alzheimers Dis. 2006 Nov;10(2-3):291-301. Review.

PMID:
17119294

Supplemental Content

Loading ...
Support Center